Ace Therapeutics has extensive experience in various types of gastrointestinal disease research and is committed to addressing the challenges our clients face in developing new drug candidates. We can offer customized preclinical services to support your research needs in Crohn's disease.
Introduction to Crohn's Disease
Crohn's disease is a chronic granulomatous inflammatory disease of unknown etiology with lesions most commonly found in the terminal ileum and adjacent colon, which may involve the entire gastrointestinal tract. The pathogenesis of Crohn's disease is closely related to a variety of factors, including environmental factors, genetics, intestinal flora and immunity.
Nowadays, the drug development strategy for Crohn's disease covers the areas of precision therapy, biologics, novel small molecule drugs and adjuvant therapy.
Biological Agents
- Anti- TNF-α Monoclonal Antibody
- Anti-Integrin Monoclonal Antibody
- Anti-Interleukin Monoclonal Antibody
- Anti-GM-CSF Monoclonal Antibody
Small Molecule Targeted Drugs
- Janus kinase (JAK) inhibitors
- T- cell and B-cell Modulators
- Sphingosine-1-Phosphate (S1P) Receptor Modulators
Fig. 1 Immuno-mediated pathogenesis of Crohn's disease. (Petagna L, et al., 2020)
What Can We Do?
According to research needs of our clients, we can provide customized services for various types of Crohn's disease research, including the animal model development, novel drug discovery, and basic research of Crohn's disease.
Crohn's Disease Model Development Services
Based on our understanding of the research needs of the pharmaceutical and biotechnology fields, we can offer the following customized Crohn's disease models.
- Chemically-induced Models
Dextran Sodium Sulfate (DSS)-induced Colitis Models
TNBS-induced Colitis Models
- Genetic Modified Models
TNF-α Overexpression Models
IL-10 Deficiency Models
Adopted T Cell Transfer Models
Basic Research Services for Crohn's Disease
Although the exact etiology of Crohn's disease is unknown, it has been reported to be the result of a combination of genetic susceptibility, an overactive immune response and environmental factors. We can offer a variety of basic research on Crohn's disease, including the discovery of highly specific biomarkers for Crohn's disease, as well as the study of potential pathogenesis by gene and protein expression, metabolites, or regulation of the intestinal flora.
Drug Development Services for Crohn's Disease
Currently, the common drug strategies for the therapy of Crohn's disease focus on reducing inflammation and controlling symptoms. Based on this, we offer the following types of novel drug discovery and development services.
- We can develop small molecule inhibitors targeting inflammatory signaling pathways to suppress the colonic inflammatory response in Crohn's disease.
- We can develop antibodies against inflammatory cytokines or immune cells that inhibit the colonic inflammatory response in Crohn's disease.
- We can explore new anti-fibrotic targets and mechanisms and develop novel anti-fibrotic drugs to reduce the intestinal fibrosis and stenosis caused by Crohn's disease.
Ace Therapeutics has years of experience providing contract research services in the field of gastrointestinal diseases. We offer customized research services based on experimental needs of our clients. If you would like to learn more about our services, please do not hesitate to contact us.
Reference
- Petagna, L.; Antonelli, A.; Ganini, C.; et al. Pathophysiology of Crohn's disease inflammation and recurrence. Biol Direct. 2020, 15(1):23.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
